Homepage > Company > Media > Pharma News > 2021 > Japan's Takeda sells four diabetes products to Teijin Pharma for $1.25 billion

Japan's Takeda sells four diabetes products to Teijin Pharma for $1.25 billion

TOKYO (Reuters) - Takeda Pharmaceutical Co said on Friday it agreed to sell four diabetes products in Japan to Teijin Pharma Ltd for 133 billion yen ($1.25 billion).

Takeda will sell the Japanese marketing rights of drugs Nesina, Liovel, Inisync and Zafatek to Teijin Pharma subject to regulator approval, the company said in a release. The drugs generated 30.8 billion yen in sales in fiscal 2019, Takeda said.

The sale is the latest in a series of deals that Takeda has undertaken to reduce debt and refocus its business after its purchase of Shire Ltd, which was completed in January 2019. ($1 = 106.0300 yen).

FEBRUARY 26, 2021

https://www.reuters.com/

Read also

Beijing institute

Beijing institute launches AI platform to boost new-drug development

Kymera Therapeutics Announces U.S.

Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis

Novartis and UK-based Relation

Novartis and UK-based Relation forge R&D deal worth up to $1.7bn

Io Therapeutics, Inc

Io Therapeutics, Inc., presents today at the San Antonio Breast Cancer Symposium preclinical studies demonstrating effectiveness of IRX4204, the company’s clinical stage retinoid X nuclear receptor ...